T cell responses in early-stage melanoma patients occur frequently and are not associated with humoral response.

ABSTRACT: Endogenous tumor-specific T cells are detectable in patients with different tumor types including malignant melanoma (MM). They can control tumor growth, have impact on patient survival and correlate with improved clinical response to immune checkpoint therapy. Thus, they may represent a potent biomarker for respective treatment decisions. So far, major target antigens of endogenous MM-reactive T cells have not been determined systematically. Instead, autoantibodies are discussed as surrogate parameter for MM-specific T cells. Throughout a period of more than 60 days after tumor resection, we therefore determined in 38 non-metastasized primary MM patients and in healthy individuals by IFNγ ELISpot and bead-based fluorescent multiplex assay major target antigens of spontaneous T cell and hu

SUBMITTER: Pfirschke C 

PROVIDER: S-EPMC11028448 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature